Navigation Links
NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution
Date:11/11/2011

LAWRENCE, Mass. and PHILADELPHIA, Nov. 11, 2011 /PRNewswire/ -- Booth # 407 at The American Society of Nephrology (ASN)'s Kidney Week 2011 -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems division has won a multi-year contract to supply the Vasc-Alert™ Access Surveillance Solution to Atlantic Dialysis Management Services centers.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

"Robust access surveillance is increasingly important for outcomes, center economics, and compliance under the new bundled payment system.  We believe Vasc-Alert's patented, automated technology simplifies and demonstrably improves a provider's ability to be effective in this area," said Mark Florence, Vice President & General Manager at Medisystems, a NxStage Company. "This agreement builds on a successful partnership between NxStage and Atlantic and demonstrates how Atlantic employs innovative new technology to improve patient care."

"After a thorough evaluation of Vasc-Alert, we believe we can reduce our rate of thrombectomy with this product technology," said J. Ganesh Bhat, M.D., Co-Principal, Atlantic Dialysis Management Services, L.L.C. "Vasc-Alert helps advance our goal of reducing hospitalizations and catheter usage. In addition, it provides a simple and convenient way to comply with CMS requirements for access surveillance without increasing staff workload."

About Vasc-Alert

Vasc-Alert, a patented medical device, uses computer technology to analyze standard treatment data taken during each patient's scheduled hemodialysis treatments to screen for vascular access dysfunction. By monitoring the data for increasing pressure trends, Vasc-Alert identifies patients who are at risk of developing a stenosis that may decrease the effectiveness of treatment or put the access site at risk of thrombosis -- a blockage that prevents the flow of blood through the access and can precipitate significant medical interventions such as thrombectomy and access revision. Weekly reports that identify at-risk patients are issued to the dialysis provider and allow the dialysis staff to proactively schedule further testing on the access. Earlier detection of access issues has the potential to lead to improved access patency, fewer hospitalizations, fewer missed treatments, and less pain, anxiety and inconvenience for patients.

About Atlantic Dialysis Management Services, L.L.C.

Atlantic Dialysis Management Services, L.L.C. was established to provide new dialysis site development, day to day administration and management of dialysis services and related business development activities. Atlantic Dialysis affiliates will provide over 250,000 dialysis treatments in 2011 to an estimated 2,500 patients in New York City and Long Island.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 20011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New FREEDOM Data Adds to Compelling Evidence in Support of More Frequent Home Hemodialysis with NxStage System One
2. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
3. NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
4. NxStage® to Report Third Quarter Fiscal 2011 Financial Results
5. NxStage Says Thank You to Patients and Care Partners at the 2nd Annual NxStageUsers Meet-Up and Conference in New Orleans
6. NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill
7. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
8. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
9. NxStage to Present at UBS Global Life Sciences Conference
10. NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award
11. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
Breaking Medicine News(10 mins):